Status: Open Not Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >
Status: Enrolling
Investigator: Tarrik Zaid
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Tanya Khan
Phone: 346.238.5655
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Tanya Khan
Phone: 346.238.5655
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >
Status: Open Not Enrolling
Investigator: Kirk Heyne
Study Coordinator: Tanya Khan
Phone: 346.238.5655
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >
Status: Open Not Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Taliah Muhammad
Phone: 346.238.4523
Primary Purpose: Treatment ... Read more >
